Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR1 | O14842 | 12/20 | 0.61 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.61 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.61 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.53 |
| ▸ | PPARD | Q03181 | 3/20 | 0.52 |
| ▸ | PPARG | P37231 | 1/20 | 0.52 |
| ▸ | PTPRC | P08575 | 1/20 | 0.51 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.51 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.51 |
| ▸ | PTGER3 | P43115 | 1/20 | 0.51 |
| ▸ | NR1H2 | P55055 | 2/20 | 0.51 |
| ▸ | NR1H3 | Q13133 | 2/20 | 0.51 |
| ▸ | RXRA | P19793 | 1/20 | 0.51 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.50 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18165305 | 0.87 | FFAR1 (0.77) | FFAR1AKR1B1FFAR4PTGER4PTGER3 | |
| SCHEMBL12585458 | 0.86 | GSTP1 (0.58) | FFAR1AKR1B1FFAR4NR4A2PPARD | |
| SCHEMBL13460872 | 0.86 | FFAR1 (0.68) | FFAR1AKR1B1FFAR4NR4A2PPARD | |
| SCHEMBL4442371 | 0.84 | MRGPRX4 (0.71) | NR4A2MRGPRX4NR1H4 | |
| SCHEMBL13460871 | 0.84 | FFAR1 (0.60) | FFAR1AKR1B1FFAR4NR4A2MRGPRX4 | |
| SCHEMBL13460992 | 0.83 | FFAR1 (0.74) | FFAR1AKR1B1FFAR4PPARDPPARG | |
| SCHEMBL7030142 | 0.83 | ACMSD (0.58) | AKR1B1RXRANR1H4 | |
| SCHEMBL13460803 | 0.83 | NR4A2 (0.66) | FFAR1FFAR4NR4A2PPARDNR1H2 | |
| SCHEMBL17954222 | 0.82 | FFAR1 (0.52) | FFAR1AKR1B1FFAR4NR4A2PPARD | |
| SCHEMBL1744794 | 0.82 | FFAR1 (0.85) | FFAR1AKR1B1FFAR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090156635-A1 | BIARYLOXYMETHYLARENECARBOXYLIC ACIDS AS GLYCOGEN SYNTHASE ACTIVATORS | GILLESPIE PAUL | 2009-06-18 | — | — | US | claimed |
| US-20060122256-A1 | Biaryloxymethylarenecarboxylic acids as glycogen synthase activators | GILLESPIE PAUL | 2006-06-08 | — | — | US | claimed |
| US-20090156635-A1 | BIARYLOXYMETHYLARENECARBOXYLIC ACIDS AS GLYCOGEN SYNTHASE ACTIVATORS | GILLESPIE PAUL | 2009-06-18 | — | — | US | disclosed |
| US-20090156635-A1 | BIARYLOXYMETHYLARENECARBOXYLIC ACIDS AS GLYCOGEN SYNTHASE ACTIVATORS | GILLESPIE PAUL | 2009-06-18 | — | — | US | disclosed |
| US-20090156635-A1 | BIARYLOXYMETHYLARENECARBOXYLIC ACIDS AS GLYCOGEN SYNTHASE ACTIVATORS | GILLESPIE PAUL | 2009-06-18 | — | — | US | disclosed |
| US-7524870-B2 | Biaryloxymethylarenecarboxylic acids as glycogen synthase activators | HOFFMANN-LA ROCHE INC. (US) | 2009-04-28 | — | — | US | disclosed |
| US-7524870-B2 | Biaryloxymethylarenecarboxylic acids as glycogen synthase activators | HOFFMANN-LA ROCHE INC. (US) | 2009-04-28 | — | — | US | disclosed |
| US-7524870-B2 | Biaryloxymethylarenecarboxylic acids as glycogen synthase activators | HOFFMANN-LA ROCHE INC. (US) | 2009-04-28 | — | — | US | disclosed |
| EP-1819691-A2 | BIARYLOXYMETHYLARENE CARBOXYLIC ACIDS | F. Hoffmann-Roche AG (CH) | 2007-08-22 | — | — | EP | disclosed |
| WO-2006058648-A2 | BIARYLOXYMETHYLARENE CARBOXYLIC ACIDS | F. HOFFMANN-LA ROCHE AG (CH) | 2006-06-08 | — | — | WO | disclosed |
| US-20060122256-A1 | Biaryloxymethylarenecarboxylic acids as glycogen synthase activators | GILLESPIE PAUL | 2006-06-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090156635-A1 | BIARYLOXYMETHYLARENECARBOXYLIC ACIDS AS GLYCOGEN SYNTHASE ACTIVATORS | GYS2, GYS1, GSK3A | FFAR1 472/4885AKR1B1 76/4885FFAR4 744/4885 |
| US-20060122256-A1 | Biaryloxymethylarenecarboxylic acids as glycogen synthase activators | GYS2, GYS1, GSK3A | FFAR1 472/4885AKR1B1 76/4885FFAR4 744/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.